Dasatinib (Dasatinib) effects and efficacy

Dasatinib (Dasatinib) is a second-generation tyrosine kinase inhibitor (TKI) used for patients with chronic, blast or accelerated phase chronic myeloid leukemia (CML) who are resistant or intolerant to previous treatments. Chronic myeloid leukemia is a malignant hematopoietic stem cell disease characterized by cells carrying the Philadelphia (Ph) chromosome, which is formed by the BCR-ABL oncogene. It effectively inhibits BCR/ABL and SRC family kinases (SRC, LCK, HCK, YES, FYN, FGR, BLK, LYN, FRK) as well as c-KIT, PDGFR-a and -b and ephrin receptor kinases.

Various clinical trials have provided evidence that it has more durable complete hematological and cytogenetic responses and is more effective in imatinib-resistant or intolerantCML, and it has also shown superiority compared with imatinib in newly diagnosed CML. Dasatinib may also have more profound effects on leukemia stem and progenitor cells and influence the tumor microenvironment than imatinib, but further confirmation is needed. Some studies have also shown that dasatinib induces defects in spindle formation, cell cycle arrest, and centrosome alterations in leukemia cells, tumor cell lines, and normal cells.

The original drug of dasatinib has been launched in China and is included in the medical insurance. Currently, reimbursement is only available to eligible patients. Common specifications The price of each box of 50mg*60 tablets may be around RMB 10,000. The original drug overseas is even more expensive. Dasatinib generics are also sold overseas. The ingredients of the drug are basically the same as those sold domestically and abroad, but the price is cheap. For example, the price of a box of 50mg*60 tablets produced by an Indian pharmaceutical factory may be several hundred yuan (the price may fluctuate due to exchange rates).